medcelerator · clinician one-pager

First FDA-Approved Gene Therapy for Glycogen Storage Disease Type Ia

GENGLYCOS (pariglasgene brecaparvovec-opnr) — one-time gene therapy to help lower daily cornstarch needs in glycogen storage disease type Ia (ages 8 and older)

FDA Approved · United States · September 11, 2026

Condition: Glycogen Storage Disease Type Ia

Who this is for

This is for people 8 years and older with glycogen storage disease type Ia who still rely on carefully timed cornstarch and may be candidates for labelled US GENGLYCOS one-time gene therapy at a Qualified Treatment Center — if anti-AAV8 antibody testing is negative and the liver is not severely scarred. It explains the first FDA-approved GSD Ia therapy, Week-48 cornstarch results, the hypoglycemic-range increase that must stay in the conversation, steroid and liver monitoring, UltraCare support, and how to talk with a metabolic genetics team — without treating cornstarch reduction as a free pass on glucose safety, a DIY import as a plan, or “approved” as funded. Authorized is not funded.

Next clinical step

The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.

Ways to access this treatment

United States · Prescription
US prescription (FDA-labelled)
https://www.fda.gov/vaccines-blood-biologics/genglycos

General resources for further research

ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/

AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/genglycos-pariglasgene-brecaparvovec